Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SynAct Pharma AB ( (SE:SYNACT) ) just unveiled an announcement.
SynAct Pharma has completed recruitment of 240 patients in its 12-week Phase 2b ADVANCE trial evaluating resomelagon in newly diagnosed rheumatoid arthritis patients starting methotrexate therapy, marking a key milestone for its lead asset in inflammatory disease. The company plans to close the database across more than 30 sites and conduct statistical analyses before releasing top-line results, which management says will guide business development discussions and could support positioning resomelagon as a safer early-stage treatment option that might delay or reduce the need for glucocorticoids, biologic DMARDs and JAK inhibitors in a growing global RA market.
The most recent analyst rating on (SE:SYNACT) stock is a Hold with a SEK22.00 price target. To see the full list of analyst forecasts on SynAct Pharma AB stock, see the SE:SYNACT Stock Forecast page.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical-stage biotechnology company listed on Nasdaq Stockholm that focuses on resolving inflammation by selectively activating the melanocortin system. The company is developing a portfolio of oral and injectable melanocortin agonists designed to induce anti-inflammatory and pro-resolution effects, targeting immune and inflammatory disorders such as rheumatoid arthritis.
Average Trading Volume: 124,560
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.16B
For a thorough assessment of SYNACT stock, go to TipRanks’ Stock Analysis page.